Table 1

Phase II trials: SVR Rate with DAA in HCVG 2-3 naives and experienced (NOT HEAD TO HEAD STUDIES)

DAA

Class

DAA Duration

PR Duration

N

SVR 4*/24 Naives

SVR 4 experienced


PR+GS-7977

NS5bPolI

12 wk

12 wk

12 wk

12 wk

8 wk

4 wk

11

10

9

11/11

10/10

10/10


GS-7977 + R

Ns5bPolI

12 wk

0

11

11/11


GS-7977+ R

Ns5bPolI

12 wk

0

25

12/15


GS7977 + Daclatasvir

    +
R

NNS5bPolI + NS5aPolI

    +
R

24 wk

24 wk

0

0

30

14

28/30*

11/14*


Abbreviations: DAA: Directly Acting Antiviral; NS5b PolI : NS5b polymerase inhibitor; NS5a Polymerase Inhibitor; PR Pegylated Interferon combined with Ribavirin; wk: week; SVR: Sustained Virologic Response; SVR 4: HCVRNA below the level of detection with Roche TaqMan assay 4 weeks after treatment withdrawal; SVR 24: HCVRNA below the level of detection with Roche TaqMan assay 24 weeks after treatment withdrawal

Puoti et al. BMC Infectious Diseases 2012 12(Suppl 2):S7   doi:10.1186/1471-2334-12-S2-S7

Open Data